Skip to main content
Print Save

Edurant FDA Approval History

FDA Approved: Yes (First approved May 20, 2011)
Brand name: Edurant
Generic name: rilpivirine
Dosage form: Tablets
Company: Tibotec Pharmaceuticals
Treatment for: HIV Infection

Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naïve).

Development timeline for Edurant

DateArticle
Jan 21, 2021Approval FDA Approves Cabenuva (cabotegravir and rilpivirine) Long-Acting Injectable HIV Treatment and Vocabria (cabotegravir) Oral HIV Treatment
May 20, 2011Approval FDA Approves New HIV Treatment Edurant (rilpivirine)
Jul 26, 2010Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration

See also

Edurant (rilpivirine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer